VEGFC and Alzheimer disease: To study how the expansion of dLVs by VEGF-C affects AD pathology, we injected 2-month-old WT and APdE9 mice i.c.v. and i.c.m. with 5 × 1010 viral particles of AAV-VC or AAV-Mock per mouse and analyzed the mice at 9 months of age (Fig. 6a).